title: FRIENDS Group: clinical and microbiological characteristics of post-filtering surgery endophthalmitis.
abstract: OBJECTIVE
  To study the clinical and microbiological characteristics as well as the prognostic factors for post-filtering surgery endophthalmitis.
  
  
  METHODS
  Twenty-three eyes were included in the study in four tertiary centres between 2004 and 2010. The clinical and microbiological data were collected prospectively (minimum follow-up, 6 months). Microbiological diagnosis was based on conventional cultures and panbacterial PCR (16SrDNA amplification and sequencing).
  
  
  RESULTS
  The onset of endophthalmitis was early (<6 weeks) in 22 % of the cases and delayed in 78 %. Elevated intraocular pressure and hypopyon were more frequent in delayed than in early presentations (p = 0.04). By combining the results of culture and panbacterial PCR, a bacterial species could be identified in 73.9 % of the cases, including 56.5 % of commensal species of the digestive tract such as Moraxella spp., oropharyngeal streptococci and Enterococcus faecalis. Good final visual acuity (VA ≥ 20/40) was correlated with initial VA greater than light perception (p = 0.05). Poor final VA (≤20/400) was correlated with a higher virulence of the infecting bacterial species (p = 0.006), and was noted in all patients with early-onset endophthalmitis.
  
  
  CONCLUSIONS
  Acute early- or delayed-onset post-filtering surgery endophthalmitis is frequently caused by bacteria of the digestive tract (e.g., Streptococcus and Enterococcus spp.). The combination of conventional cultures and panbacterial PCR allowed us to identify the causative microorganism in three-quarters of the cases, i.e., 21 % more cases than through culture alone. Despite adequate antibiotic and surgical treatment, the anatomical and visual prognosis remains poor.
authors.affiliation: UJF-Grenoble 1, Grenoble, F-38041, France.
authors.forename: E
authors.initials: E
authors.lastname: Brillat-Zaratzian
authors.forename: A
authors.initials: A
authors.lastname: Bron
authors.forename: F
authors.initials: F
authors.lastname: Aptel
authors.forename: J P
authors.initials: JP
authors.lastname: Romanet
authors.forename: P L
authors.initials: PL
authors.lastname: Cornut
authors.forename: F
authors.initials: F
authors.lastname: Vandenesch
authors.forename: S
authors.initials: S
authors.lastname: Boisset
authors.forename: M
authors.initials: M
authors.lastname: Maurin
authors.forename: C
authors.initials: C
authors.lastname: Chiquet
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001082:Aqueous Humor / Q000382:microbiology; D002442:Ceftazidime / Q000627:therapeutic use; D004269:DNA, Bacterial / Q000235:genetics; D004275:DNA, Ribosomal / Q000235:genetics; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D016983:Enterococcus / Q000302:isolation & purification; D015818:Eye Infections, Bacterial / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D018463:Filtering Surgery; D005901:Glaucoma / Q000601:surgery; D016908:Gram-Positive Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D013290:Streptococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D013291:Streptococcus / Q000302:isolation & purification; D014640:Vancomycin / Q000627:therapeutic use; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S; D014640:Vancomycin; D002442:Ceftazidime